Payment overview · 2025
General Payments
$541.77
35 reported records · 11 companies
Healthcare provider profile · identity verified
Joseph A Calamia, DO
Allopathic & Osteopathic Physicians|Family Medicine · NORRISTOWN, PA · NPI 1841279551
Verified facts
What the public records show
CMS Open Payments records show Joseph A Calamia, DO received $541.77 in general payments during 2025 across 35 reported records.
ABBVIE INC. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $178.22 | 32.9% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.91 | 26.0% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.78 | 9.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.39 | 6.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.00 | 4.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.83 | 4.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.86 | 3.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.91 | 3.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.34 | 3.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.06 | 3.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.47 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $541.77 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $99.29 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $87.08 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.26 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.78 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.99 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 175 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 32 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
111 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
175 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 670 | 205 |
| Levothyroxine Sodium | Levothyroxine Sodium | 437 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 384 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 372 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 371 | 112 |
| Metformin Hcl | Metformin Hcl | 334 | 91 |
| Gabapentin | Gabapentin | 308 | 67 |
| Lorazepam | Lorazepam | 274 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 259 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 81 |
| Lisinopril | Lisinopril | 243 | 73 |
| Losartan Potassium | Losartan Potassium | 218 | 63 |
| Simvastatin | Simvastatin | 217 | 60 |
| Omeprazole | Omeprazole | 210 | 63 |
| Sertraline Hcl | Sertraline Hcl | 209 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 70 |
| Ozempic | Semaglutide | 175 | 36 |
| Furosemide | Furosemide | 153 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 40 |
| Trazodone Hcl | Trazodone Hcl | 144 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 41 |
| Bupropion Xl | Bupropion Hcl | 131 | 40 |
| Famotidine | Famotidine | 129 | 38 |
| Alprazolam | Alprazolam | 127 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 33 |
| Allopurinol | Allopurinol | 125 | 33 |
| Eliquis | Apixaban | 114 | 25 |
| Synthroid | Levothyroxine Sodium | 111 | 27 |
| Prednisone | Prednisone | 110 | 71 |
| Clonazepam | Clonazepam | 109 | 17 |
| Jardiance | Empagliflozin | 109 | 27 |
| Metformin Hcl Er | Metformin Hcl | 109 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 105 | 75 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 25 |
| Carvedilol | Carvedilol | 101 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 21 |
| Methylprednisolone | Methylprednisolone | 97 | 87 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 28 |
| Celecoxib | Celecoxib | 92 | 27 |
| Montelukast Sodium | Montelukast Sodium | 92 | 28 |
| Donepezil Hcl | Donepezil Hcl | 90 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 28 |
| Meloxicam | Meloxicam | 81 | 26 |
| Azithromycin | Azithromycin | 80 | 58 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 80 | 21 |
| Mirtazapine | Mirtazapine | 78 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 19 |
| Aripiprazole | Aripiprazole | 72 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 20 |
| Pregabalin | Pregabalin | 72 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 18 |
| Farxiga | Dapagliflozin Propanediol | 69 | 15 |
| Mounjaro | Tirzepatide | 68 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 63 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 47 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | suppressed |
| Valsartan | Valsartan | 53 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Ibuprofen | Ibuprofen | 49 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 12 |
| Glipizide | Glipizide | 46 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 19 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | 18 |
| Risperidone | Risperidone | 43 | 14 |
| Finasteride | Finasteride | 41 | 14 |
| Glimepiride | Glimepiride | 41 | 17 |
| Ketoconazole | Ketoconazole | 40 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 14 |
| Valacyclovir | Valacyclovir Hcl | 39 | 16 |
| Diazepam | Diazepam | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Atenolol | Atenolol | 36 | 12 |
| Glipizide Er | Glipizide | 36 | 11 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 16 |
| Baclofen | Baclofen | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 32 | 30 |
| Cephalexin | Cephalexin | 32 | 23 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 14 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 12 |
| Colchicine | Colchicine | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 19 |
| Potassium Chloride | Potassium Chloride | 30 | 12 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | 11 |
| Amoxicillin | Amoxicillin | 26 | 20 |
| Bumetanide | Bumetanide | 26 | 11 |
| Nadolol | Nadolol | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 12 |
| Fluconazole | Fluconazole | 25 | 17 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 20 | 20 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Cartia Xt | Diltiazem Hcl | 16 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $541.77 · 35 records | ABBVIE INC. | AIRSUPRA, CAMZYOS, CAPLYTA, Cologuard Collection Kit, MOUNJARO, Ozempic, PAXLOVID, QULIPTA, Rybelsus, Symbravo, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error